MPN Advances Day 2017 | Integrating molecular variables into prognostic models for patients with MPNs
Alessandro Vannucchi
• 18 Nov 2017
In this interview, Alessandro Vannucchi, MD, of the University of Florence, Florence, Italy, talks about the new models that doctors can use to determine the prognoses for patients with myeloproliferative neoplasms (MPNs), such as thrombosis for essential thrombocythemia or survival in myelofibrosis patients. Dr Vannucchi highlights how these new models take into account particular mutations, which can affect an individual’s chance of reaching a certain endpoint, and can therefore be used by clinicians to assess whether a patient requires a certain therapy, such as stem cell transplantation. This video was recorded at the Myeloproliferative Neoplasms Advances Day 2017 in London, UK.
